These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 24681837)
1. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837 [TBL] [Abstract][Full Text] [Related]
2. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Moulis G; Sommet A; Lapeyre-Mestre M; Montastruc JL; Rheumatology (Oxford); 2014 Oct; 53(10):1864-71. PubMed ID: 24899660 [TBL] [Abstract][Full Text] [Related]
3. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Williams VL; Cohen PR Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984 [TBL] [Abstract][Full Text] [Related]
4. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. Mendes D; Alves C; Batel-Marques F J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532 [TBL] [Abstract][Full Text] [Related]
5. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system. Théophile H; Schaeverbeke T; Miremont-Salamé G; Abouelfath A; Kahn V; Haramburu F; Bégaud B Drug Saf; 2011 Jul; 34(7):577-85. PubMed ID: 21663333 [TBL] [Abstract][Full Text] [Related]
6. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483 [TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors]. Amano K Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139 [No Abstract] [Full Text] [Related]
9. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Mitoma H; Horiuchi T; Tsukamoto H; Ueda N Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553 [TBL] [Abstract][Full Text] [Related]
10. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984 [TBL] [Abstract][Full Text] [Related]
11. Potential use of TNF-α inhibitors in systemic sclerosis. Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073 [TBL] [Abstract][Full Text] [Related]
12. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486 [TBL] [Abstract][Full Text] [Related]
13. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials. Liu Y; Fan W; Chen H; Yu MX Asian Pac J Cancer Prev; 2014; 15(8):3403-10. PubMed ID: 24870729 [TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322 [TBL] [Abstract][Full Text] [Related]
15. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. Karampetsou MP; Liossis SN; Sfikakis PP QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008 [TBL] [Abstract][Full Text] [Related]
16. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557 [TBL] [Abstract][Full Text] [Related]
17. [Anti-tumor necrosis factor-α medications and pregnancy]. Simon PC; Vallano A Med Clin (Barc); 2013 Sep; 141(6):257-9. PubMed ID: 23702347 [No Abstract] [Full Text] [Related]
18. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Machado MA; Barbosa MM; Almeida AM; de Araújo VE; Kakehasi AM; Andrade EI; Cherchiglia ML; Acurcio Fde A Rheumatol Int; 2013 Sep; 33(9):2199-213. PubMed ID: 23686218 [TBL] [Abstract][Full Text] [Related]
19. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia. Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578 [TBL] [Abstract][Full Text] [Related]
20. Is there a link between amyotrophic lateral sclerosis and treatment with TNF-alpha inhibitors? Börjesson A; Grundmark B; Olaisson H; Waldenlind L Ups J Med Sci; 2013 Aug; 118(3):199-200. PubMed ID: 23560624 [No Abstract] [Full Text] [Related] [Next] [New Search]